205 related articles for article (PubMed ID: 23773558)
1. Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?
Niegisch G; Lorch A; Droller MJ; Lavery HJ; Stensland KD; Albers P
Eur Urol; 2013 Sep; 64(3):355-7. PubMed ID: 23773558
[TBL] [Abstract][Full Text] [Related]
2. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.
Stenzl A; Cowan NC; De Santis M; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
Eur Urol; 2011 Jun; 59(6):1009-18. PubMed ID: 21454009
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
4. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
[TBL] [Abstract][Full Text] [Related]
5. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.
Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Vavassori I; Barni S
Eur Urol; 2014 Feb; 65(2):350-7. PubMed ID: 23849998
[TBL] [Abstract][Full Text] [Related]
6. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.
Gray PJ; Fedewa SA; Shipley WU; Efstathiou JA; Lin CC; Zietman AL; Virgo KS
Eur Urol; 2013 May; 63(5):823-9. PubMed ID: 23200811
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy in patients with invasive bladder cancer.
Vaughn DJ; Malkowicz SB
Urol Clin North Am; 2005 May; 32(2):231-7. PubMed ID: 15862620
[TBL] [Abstract][Full Text] [Related]
8. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.
Flaig TW; Spiess PE; Agarwal N; Bangs R; Boorjian SA; Buyyounouski MK; Downs TM; Efstathiou JA; Friedlander T; Greenberg RE; Guru KA; Hahn N; Herr HW; Hoimes C; Inman BA; Jimbo M; Kader AK; Lele SM; Meeks JJ; Michalski J; Montgomery JS; Pagliaro LC; Pal SK; Patterson A; Petrylak DP; Plimack ER; Pohar KS; Porter MP; Preston MA; Sexton WJ; Siefker-Radtke AO; Tward J; Wile G; Johnson-Chilla A; Dwyer MA; Gurski LA
J Natl Compr Canc Netw; 2018 Sep; 16(9):1041-1053. PubMed ID: 30181416
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
[TBL] [Abstract][Full Text] [Related]
10. Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer.
Milowsky MI; Stadler WM; Bajorin DF
BJU Int; 2008 Nov; 102(9 Pt B):1339-44. PubMed ID: 19035902
[TBL] [Abstract][Full Text] [Related]
11. Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer.
Izawa JI; Chin JL; Winquist E
Can J Urol; 2006 Jun; 13 Suppl 3():48-53. PubMed ID: 16818012
[TBL] [Abstract][Full Text] [Related]
12. Management of muscle-invasive bladder cancer in the elderly.
Rose TL; Milowsky MI
Curr Opin Urol; 2015 Sep; 25(5):459-67. PubMed ID: 26075567
[TBL] [Abstract][Full Text] [Related]
13. The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer.
deVere White RW; Katz MH; Steinberg GD
J Urol; 2009 May; 181(5):1994-7. PubMed ID: 19286209
[No Abstract] [Full Text] [Related]
14. Adjuvant Chemotherapy Is More Suitable Than Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer Patients Treated With Radical Chemoradiotherapy.
Joseph N; Choudhury A
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):614-6. PubMed ID: 27681756
[No Abstract] [Full Text] [Related]
15. [Chemotherapy for urothelial cancer of the bladder--update 2012].
Niegisch G; Lorch A; Albers P
Aktuelle Urol; 2012 Dec; 43(6):412-9. PubMed ID: 23196781
[TBL] [Abstract][Full Text] [Related]
16. [Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma].
Stenzl A; Cowan NC; De Santis M; Jakse G; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
Actas Urol Esp; 2010 Jan; 34(1):51-62. PubMed ID: 20223133
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic options and treatment of muscle invasive bladder cancer.
O'Connor RC; Alsikafi NF; Steinberg GD
Expert Rev Anticancer Ther; 2001 Dec; 1(4):511-22. PubMed ID: 12113083
[TBL] [Abstract][Full Text] [Related]
18. Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer?
Niegisch G; Albers P
Curr Opin Urol; 2011 Sep; 21(5):434-9. PubMed ID: 21738037
[TBL] [Abstract][Full Text] [Related]
19. Advances in the management of muscle-invasive bladder cancer through risk prediction, risk communication, and novel treatment approaches.
Galsky MD; Domingo-Domenech J
Clin Adv Hematol Oncol; 2013 Feb; 11(2):86-92. PubMed ID: 23598909
[TBL] [Abstract][Full Text] [Related]
20. [Effects of neoadjuvant chemotherapy on the prognostic mortality risk of invasive transitional bladder cancer: a meta-analysis].
Fan B; Zhang L; Li XC; Song YS; Guo EZ; Pan T; Shen L; Xin SY; Song XS; Wang JB
Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(22):1705-10. PubMed ID: 24124676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
